ARO ALK7
Alternative Names: ARO-ALK7Latest Information Update: 03 Sep 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Obesity therapies; Small interfering RNA
- Mechanism of Action ACVR1C protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 20 Aug 2024 Arrowhead Pharmaceuticals announces intention to submit clinical trial applications with regulatory authorities for Obesity and Metabolic disorders in late 2024
- 20 Aug 2024 Arrowhead Pharmaceuticals plans a clinical trial in Obesity (In volunteers) in early 2025
- 14 Aug 2024 Preclinical trials in Obesity in USA (Parenteral) prior to August 2024 (Arrowhead Pharmaceuticals plans a clinical trial in Obesity (In volunteers) in early 2025